Skip to main content
SpringerLink
Log in

Das metastasierte Mammakarzinom

Umsetzung des Fortschritts in die onkologische Praxis

  • TOPIC 1 · metastasiertes mammakarzinom
  • Published:
best practice onkologie Aims and scope

Eine vielfältige klinische und zellbiologisch-experimentelle Forschungslandschaft trägt dazu bei, dass gerade beim metastasierten Mammakarzinom die zunehmenden therapeutischen Alternativen einer medikamentösen Behandlung nicht nur einem steten Wandel unterworfen sind, sondern glücklicherweise auch zu einer schrittweisen Verbesserung der Langzeitergebnisse führen [1]. Wie bei der einzelnen Patientin zu verfahren ist, wird durch die onkologischen Therapeuten oft recht unterschiedlich beurteilt. Auch aus Sicht der Autoren sind bei den zahlreichen unterschiedlichen Situationen eines Langzeitverlaufs die Behandlungsmöglichkeiten heterogen. Diese können durch die gegenwärtige Studienmedizin nur teilweise abgebildet werden [2]. Deshalb sind Vorgaben durch vereinfachende Leitlinien von Fachgesellschaften auch nicht immer befriedigend.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Giordano SH, Budzar AU, Smith TL et al. (2004) Is breast cancer survival improving? Cancer 100: 44–52

    Article  PubMed  Google Scholar 

  2. Seeber S, Braun AH (2005) Phase III trials in oncology: setting standards of care? Nat Clin Pract Oncol 2: 426–427

    Article  PubMed  Google Scholar 

  3. Miller K, Wang M, Gralow J et al. (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357: 2666–2676

    Article  PubMed  CAS  Google Scholar 

  4. Fisher B, Brown A, Mamounas E et al. (1997) Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15: 2483–2493

    PubMed  CAS  Google Scholar 

  5. O'Shaughnessy J, Miles D, Vukelja S et al. (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer. J Clin Oncol 20: 2812–2823

    Article  PubMed  Google Scholar 

  6. Feher O, Vodvarka P, Jassem J et al. (2005) First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study. Ann Oncol 16: 899–908

    Article  PubMed  CAS  Google Scholar 

  7. Sledge GW, Neuberg D, Bernardo P et al. (2003) Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 21: 588–592

    Article  PubMed  Google Scholar 

  8. Welt A, Minckwitz G v, Oberhoff C et al. (2005) Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer. Ann Oncol 16: 64–69

    Article  PubMed  CAS  Google Scholar 

  9. Bojko P, Welt A, Schleucher R et al. (2004) High-dose chemotherapy with autologous stem cell transplantation in patients with oligometastatic breast cancer. Bone Marrow Transplant 34: 637–643

    Article  PubMed  CAS  Google Scholar 

  10. Hortobagyi GN (2002) Can we cure limited metastatic breast cancer? J Clin Oncol 20: 620–623

    PubMed  Google Scholar 

  11. Goncalves A, Deblock M, Esterni B et al. (2007) Serum proteomic prediction of progression-free survival in HER2-negative metastatic breast cancer patients receiving docetaxel as first-line treatment. J Clin Oncol (ASCO Meeting Abstract) 25: 1010

    Google Scholar 

  12. Kaufman PA, Broadwater G, Lezon-Geyda K et al. (2007) CALGB 150002: Correlation of HER2 and chromosome 17 (ch17) copy number with trastuzumab (T) efficacy in CALGB 9840, paclitaxel (P) with or without T in HER2+ and HER2− metastatic breast cancer (MBC). J Clin Oncol (ASCO Meeting Abstract) 25: 1009

    Google Scholar 

  13. Lin NU, Dieras V, Paul D et al. (2007) EGF105084, a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (H) based systemic therapy and cranial radiotherapy (RT). J Clin Oncol (ASCO Meeting Abstract) 25: 1012

    Google Scholar 

  14. Seidman A (2005) „Will weekly work“? Seems to be so… . J Clin Oncol 23: 5873–5874

    Article  PubMed  Google Scholar 

  15. Verrill MW, Lee J, Cameron A et al. (2007) Anglo-Celtic IV: First results of a UK National Cancer Research Network randomised phase 3 pharmacogenetic trial of weekly versus 3 weekly Paclitaxel in patients with locally advanced or metastatic breast cancer. J Clin Oncol (ASCO Meeting Abstract) 25: 1005

    Google Scholar 

  16. Alba E, Ruiz-Borrego M, Martín M et al. (2007) Prolongation of TTP by maintenance therapy with PLD in a multicenter phase III randomited trial following standard chemotherapy for MBC: GEICAM 2001–01 study. J Clin Oncol (ASCO Meeting Abstract) 25: 1007

    Google Scholar 

  17. Slamon DJ, Mackey J, Robert N et al. (2007) Role of anthracycline- based therapy in the adjuvant treatment of breast cancer: Efficacy analyses determined by molecular subtypes of the disease. 30th Annual San Antonio Breast Cancer Symposium: Abstr. 13

  18. Rakha EA, El-Sayed ME, Reis-Filho J, Ellis IO (2008) Patho-biological aspects of basal-like breast cancer. Breast Cancer Res Treat. 2008 Mar 9 [Epub ahead of print]

  19. Rugo HS, Thomas ES, Lee RK et al. (2007) Combination therapy with the novel epothilone B analog, ixabepilone, plus capecitabine has efficacy in ER/PR/HER2-negative breast cancer resistant to anthracyclines and taxanes. 30th Annual San Antonio Breast Cancer Symposium: Abstr. 6069

  20. Welt A, Schütte J, Seeber S (2007) Mammakarzinom. In: Seeber S, Schütte J (Hrsg) Therapiekonzepte Onkologie. 5. Aufl., Springer, Berlin, S 1119–1183

  21. Walter C (2008) Nichtpublizierte Fallsammlung von Patientinnen mit Langzeitüberleben bei metastasiertem Mammakarzinom der Inneren Klinik (Tumorforschung) des Universitätsklinikums Essen

Download references

Author information

Authors and Affiliations

  1. Klinik für Internistische Onkologie/Hämatologie, Kliniken Essen-Mitte/Evangelische Huyssens-Stiftung, Essen

    S. Seeber

  2. Innere Klinik (Tumorforschung), Westdeutsches Tumorzentrum, Universitätsklinikum Essen, Essen

    A. Welt

  3. Klinik für Internistische Onkologie/Hämatologie, Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung, 45136, Essen

    S. Seeber

  4. Innere Klinik (Tumorforschung), Westdeutsches Tumorzentrum, Universitätsklinikum Essen, 45147, Essen

    A. Welt

Authors
  1. S. Seeber
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Welt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to S. Seeber or A. Welt.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Seeber, S., Welt, A. Das metastasierte Mammakarzinom. best practice onkologie 3, 4–16 (2008). https://doi.org/10.1007/s11654-008-0047-6

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11654-008-0047-6

Search

Navigation